Efficacy of canakinumab for mosaic tumor necrosis factor receptor associated periodic syndrome.

Authors :: Terré A
Vautier M
Kahn JE
Georgin-Lavialle S
Boursier G
Source :: European journal of internal medicine [Eur J Intern Med] 2024 May; Vol. 123, pp. 156-158. Date of Electronic Publication: 2024 Feb 02.
Publication Year :: 2024
Abstract: Competing Interests: Declaration of competing interest SGL received Travel grants and honoraria from the SOBI and Novartis laboratories.

Subjects :: Female
Humans
Male
Antibodies, Monoclonal therapeutic use
Fever drug therapy
Hereditary Autoinflammatory Diseases drug therapy
Receptors, Tumor Necrosis Factor, Type I genetics
Treatment Outcome
Adult
Middle Aged
Antibodies, Monoclonal, Humanized therapeutic use

Full Text Access

Tools